Our Mission
We exist to solve one of medicine’s most urgent challenges: the diagnostic gap in rare and complex diseases.
At ARCHIMEDlife, we develop and deliver diagnostic tools and services that not only identify patients faster — but that also support life-saving therapies, enable clinical trials, and advance precision medicine.
We combine biochemistry, genetics, immunology, and digital connectivity in a disease-focused model that serves the needs of clinicians and patients — not just technologies.
Every test we perform is a step closer to an answer. Every result, a pathway to treatment. Every partnership, a shared mission to transform lives.
Our Vision
At ARCHIMEDlife, our vision is to be one of the world’s leading diagnostics partners for rare and complex diseases — combining proprietary assays, deep pharma collaborations, and science with a globally scalable, digital-first infrastructure.
Through our lean operating model, IVDR-ready reagent production (ARCHImedline), and our proprietary digital physician platform (WEBPORTAL), we are building a vertically integrated, digitally enabled, physician-trusted diagnostics platform — positioned for sustainable growth across Europe, MENA, LATAM, and Southeast Asia.
In a field marked by fragmentation and unmet need, ARCHIMEDlife offers a rare asset: a high-impact diagnostics and service engine that bridges patients, physicians, and pharma with precision and purpose. With focused investments across our R&D activities, compliance, and commercialization, we are scaling globally — and deepening a defensible advantage in one of the most critical frontiers of medicine.
A Message from Our CEO, Dr. David C. Kasper
“Since founding ARCHIMEDlife in 2013, our mission has remained clear: to provide faster, better, and more meaningful diagnostic answers — for patients, families, and physicians around the world.
What began as a pioneering laboratory for rare disease diagnostics has grown into a globally recognized, technology-enabled platform combining different technologies such as clinical mass spectrometry, next-generation sequencing now including long-read, and innovative biomarker discovery as well as immunology. Today, we partner with leading physicians, researchers, and pharmaceutical companies to deliver precision diagnostics at the moment they matter most.
We believe that access to high-quality, actionable health data is not just a technical challenge — it’s a human one. That’s why we are committed to developing novel, integrated tests that transform uncertainty into clarity, and delay into timely intervention.
I invite you to share your ideas with us. Let’s shape the future of laboratory medicine together — with science, empathy, and collaboration at its core.”
— Dr. David C. Kasper
Founder & CEO, ARCHIMEDlife & ARCHImedline
VP International Business, amedes group